BOSTER
antibody and ELISA experts

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com

Anti-DR5 TNFRSF10B Antibody

Catalog Number: A00410-2

About TNFRSF10B

Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family. DR4 was recently identified as the receptor for TRAIL. A novel death domain containing receptor for TRAIL was more recently identified and designated DR5, Apo2, TRAIL-R2, TRICK2, or KILLER by several groups independently. Like DR4, DR5 transcript is widely expressed in normal tissues and in many types of tumor cells. DR5 binds to TRAIL and mediates TRAIL induced cell death. Overexpression of DR5 induces apoptosis and activates NF-kappaB.

Overview

Product Name	Anti-DR5 TNFRSF10B Antibody
Reactive Species	Human, Mouse, Rat
Description	Boster Bio Anti-DR5 TNFRSF10B Antibody (Catalog # A00410-2). Tested in ELISA, WB, IHC-P, IF applications. This antibody reacts with Human, Mouse, Rat.
Application	ELISA, IF, IHC-P, WB
Clonality	Polyclonal
Formulation	DR5 Antibody is supplied in PBS containing 0.02% sodium azide.
Storage Instructions	DR5 antibody can be stored at 4°C up to one year. Antibodies should not be exposed to prolonged high temperatures.
Host	Rabbit
Uniprot ID	O14763

Technical Details

Immunogen	DR5 antibody was raised against a peptide corresponding to 20 amino acids near the carboxy terminus of human DR5 precursor. The immunogen is located within the last 50 amino acids of DR5.
Predicted Reactive Species	Bovine, Pig, Rat
Cross Reactivity	Antibody has no cross reaction to DR4.
Isotype	IgG
Form	Liquid
Concentration	1 mg/ml
Purification	DR5 Antibody is affinity chromatography purified via peptide column.

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com

Suggested Dilutions	WB: 0.5-2 ug/mL; IHC-P: 5 ug/mL; IF: 5-10 ug/mL. Antibody validated: Western Blot in human, mouse and rat samples; Immunohistochemistry in mouse samples; Immunocytochemistry in human samples and Immunofluorescence in human, mouse and rat samples. All other applications and species not yet tested. Optimal dilutions for each application should be determined by the researcher.

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com

Anti-DR5 TNFRSF10B Antibody (A00410-2) Images



Western Blot Validation in Human Cell Lines Loading: 15 ug of lysates per lane. Antibodies: DR5 A00410-2, (0.5 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.



Western Blot Validation in Human HepG2 Cells Loading: 15 ug of lysates per lane. Antibodies: DR5 A00410-2, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 1 ug/mL Lane 2: 2 ug/mL Lane 3: 4 ug/mL



Western Blot Validation in Mouse and Rat Cell Lines Loading: 15 ug of lysates per lane. Antibodies: DR5 A00410-2, (2 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP



Western Blot Validation in Mouse Cell Lines Loading: 15 ug of lysates per lane. Antibodies: DR5 A00410-2, (1 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Western Blot Validation in Mouse Heart Loading: 15 ug of lysatesper lane. Antibodies: DR5 A00410-2, (1 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com





Western Blot Validation in Rat Skeletal Muscle Loading: 15 ug of lysate per lane. Antibodies: DR5 A00410-2, (1 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.



Immunofluorescence Validation of DR5 in Human HepG2 Cells Immunofluorescent analysis of 4% paraformaldehyde-fixed human HepG2 cells labeling DR5 with A00410-2 at 5 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI (blue).



Immunofluorescence Validation of DR5 in Human Testis Immunofluorescent analysis of 4% paraformaldehyde-fixed human testis tissue labeling DR5 with A00410-2 at 10 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI (blue).



Immunofluorescence Validation of DR5 in Mouse Pancreas Immunofluorescent analysis of 4% paraformaldehyde-fixed mouse pancreas tissue labeling DR5 with A00410-2 at 10 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI (blue).

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com



Immunofluorescence Validation of DR5 in Rat Brain Immunofluorescent analysis of 4% paraformaldehyde-fixed rat brain tissue labeling DR5 with A00410-2 at 5 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI (blue).



KO Validation of DR5 in HCT116 Cells (Han et al., 2015) Anti-cancer drug, Carfilzomib (CFZ), induced up-regulation of DR5 and the expression of DR5 was not detected in DR5-KO HCT 116 cell line with anti-DR5 antibodies (A00410-2).



KD Validation of DR5 in MB231 Cells (Rahman et al., 2009) Western blot analysis with anti-DR5 antibodies was performed for DR5 in MB231 cells transfected with control siRNA or DR5 siRNA. DR5 expression was disrupted after DR5 siRNA knockdown.



Immunohistochemistry Validation of DR5 in Mouse kidney tissue Immunohistochemical analysis of paraffin-embedded mouse kidney tissue using anti-DR5 antibody (A00410-2) at 5ug/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.



Immunohistochemistry Validation of BIM in Human Colon Tumors (Devetzi et al., 2016) Protein analysis for DR5 by immunohistochemistry with anti-DR5 antibodies in human colon tumors. Strong immunoreactivity is shown for DR5 in T167 patient with colorectal cancer.

Regulated Expression Validation of DR5 in Thyroid Epithelial Cells (Bretz et al., 2002) Immunostaining with anti-DR5 antibodies shows high levels of DR5 expression in untreated cells and cells treated with each of the three cytokines alone or TNFalpha combined with IL-1b. In contrast, treatment with both IFNg and TNFalpha or all three cytokines greatly reduces DR5 staining. The reduction in staining appears

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com



most significant in cytoplasmic regions while some staining is maintained in or around the nucleus.

Anti-DR5 TNFRSF10B Antibody

For Research Use Only. Not for use in diagnostic procedures.